TickerFacts.

Liminatus Pharma, Inc. (LIMN): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$9.81M
As of 2025-12-31
$300.6K
As of 2026-06-30
2024-12-31: -$19.34M2025-12-31: -$9.81M-$9.81M
2024-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$9.81Mn/m2026-03-31, Balance as of period end
2024-12-31-$19.34Mn/a2026-03-31, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Liminatus Pharma, Inc. (LIMN)2025-12-31-$9.81Mn/m
Adaptin Bio, Inc. (APTN)2025-12-31-$1.49Mn/m
Brainstorm Cell Therapeutics Inc. (BCLI)2025-12-31-$9.98Mn/m
Abpro Holdings, Inc. (ABPO)2025-12-31-$8.83Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$1.42Mn/m
Zivo Bioscience, Inc. (ZIVO)2024-12-31-$514.9Kn/m
Estrella Immunopharma, Inc. (ESLA)2025-12-31-$10.37Mn/m
BioCardia, Inc. (BCDA)2025-12-31$895.0K+6.9%
Cero Therapeutics Holdings, Inc. (CERO)2025-12-31-$5.45Mn/m

Compare LIMN, APTN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗